Shawn M. Carter is an Online Content Editor at Healio Nephrology. With a strong background in medical journalism, he has covered a range of topics including endocrinology and remote healthcare, drawing from his experiences at prominent newsrooms like CNBC and Fox Business. Carter's work has been featured in outlets such as Forbes and Acorns, showcasing his commitment to producing quality healthcare content.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Shawn M. Carter's articles primarily focus on nephrology, kidney health, dialysis, transplantation, and kidney disease. The coverage attributes indicate a heavy reliance on data citations (98%) with themes covering scientific research (55%) and healthcare & pharmaceuticals (29%).
If you are considering reaching out to Shawn M. Carter with a pitch or contribution related to the topics covered in his articles, it would be beneficial to offer fact-based insights supported by credible data within the field of nephrology. Additionally, providing information about recent studies or developments in the areas of kidney health, dialysis, transplantation or kidney disease is likely to align well with his coverage interests.
Given that there is no specific geographic focus indicated for this journalist's work, pitches should emphasize globally relevant trends and findings within nephrology and related fields.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Shawn M. Carter
GLP-1 receptor agonists may reduce the likelihood of mortality and increase odds for transplant wait-listing for patients with kidney disease and type 2 diabetes, according to researchers.In January, the first GLP-1 receptor agonist, semaglutide (Ozempic, Novo Nordisk), was approved by the FDA for use by adults with type 2 diabetes and chronic kidney disease to reduce the risk for worsening CKD
Worldwide prevalence of kidney failure requiring dialysis nearly tripled since 1990 to reach 4.6 million cases in 2023, according to results of the Global Burden of Disease study 2023.Researchers reported differences in the number of diagnoses across regions, as well as between men and women. The analysis also found that type 2 diabetes and hypertension were the leading drivers of kidney failure
By: Richard Smith, Shawn M. Carter
Prophylactic antibiotic use before tunneled cuffed catheter insertion was not linked to a lower rate of early hemodialysis catheter-related bloodstream infections, a study found.
Once you've opened an IRA, you should invest your IRA contributions. Make sure you understand the fees for and investments in your account.
